Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Benzodioxoles/administration & dosage"'
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Autor:
Daniel Peckham, Paul Whitaker, Anil Mehta, Sinisa Savic, Michael F. McDermott, T. Scambler, J. Holbrook, Christine Etherington, Ian Clifton, Heledd H. Jarosz-Griffiths, Samuel Lara-Reyna, Giulia Spoletini, C. Wong, Fabio Martinon
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
Previously, we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al. eLife 2019). Here we show that CFTR modulato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c3b19820b0ec649de1acb486b5ee6
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
Autor:
VX17-445-103 Trial Group
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989
https://dspace.library.uu.nl/handle/1874/391989
Objectives: To evaluate the effects of topically and subconjunctivally administered sesamol on experimentally induced corneal neovascularization in rats. Methods: Fifty-six right eyes of 56 Wistar Albino rats were chemically cauterized to induce corn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d76a639c1d3e3e72ab248933e20f12